[Clinical results and experiences with combination of radiotherapy and radiosensitizing agents].
Clinical results and experiences with the combination of radiotherapy and radiosensitizing agents to the head and neck cancers were reported. Each of chemotherapeutic agents, 5-FU, Bleomycin, Peplomycin, Adriamycin, and Cisplatin had a radiosensitizing effect, and was expected to affect additively to radiotherapy, which led to the improvement of local control rate, reduction of dose of external radiotherapy by 10-20 Gy/1-2 weeks or more, or reduction or dispersion of treatment-related injury. Especially in the management of head and neck cancers, those merits also led to the preservation of function or cosmesis and the saving from the radical surgery in a substantial amount of cases. It was also stressed that the judgment of whether or not the salvage surgery/brachytherapy is necessary must be critically done for each case during the RT course.
Ikeda
H
H
Dept. of Radiation Oncology, Osaka Univ. Med. School.
D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D017663:Peplomycin; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011879:Radiotherapy Dosage
D011838:Radiation-Sensitizing Agents; D001761:Bleomycin; D017663:Peplomycin; D004317:Doxorubicin; D002945:Cisplatin